vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v18i6.2069vsp-2263Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEОсобенности течения и основные подходы к топической терапии пиодермий в детском возрастеFeatures and Basic Approaches to Pyoderma Topical Treatment in Childrenhttps://orcid.org/0000-0003-2252-8570МурашкинН. Н.MurashkinNikolay N.

Мурашкин Николай Николаевич - доктор медицинских наук, профессор, заведующий отделением дерматологии с группой лазерной хирургии НМИЦ здоровья детей; заведующий лабораторией патологии кожи у детей отдела научных исследований в педиатрии НМИЦ здоровья детей; профессор кафедры дерматовенерологии и косметологии ЦГМА; профессор кафедры педиатрии и детской ревматологии Первого МГМУ им.И.М. Сеченова

119991, Москва, Ломоносовский пр-т, д. 2, стр. 1, тел.: +7 (495) 967-14-20

Moscow

m_nn2001@mail.ruhttps://orcid.org/0000-0002-0858-8780ОпрятинЛ. А.OpryatinLeonid A.

Москва

Moscow

https://orcid.org/0000-0002-4107-4642ЕпишевР. В.EpishevRoman V.

Москва

Moscow

https://orcid.org/0000-0002-6034-8231МатерикинА. И.MaterikinAlexander I.

Москва

Moscow

https://orcid.org/0000-0002-8232-8936АмбарчянЭ. Т.AmbarchyanEduard T.

Москва

Moscow

https://orcid.org/0000-0002-0081-0981ИвановР. А.IvanovRoman A.

Москва

Moscow

Национальный научно-практический центр здоровья детей; Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет); Центральная государственная медицинская академия Управления делами Президента Российской ФедерацииРоссияNational Medical Research Center of Children's Health; Sechenov First Moscow State Medical University (Sechenov University); Central State Medical Academy of Department of Presidential AffairsRussian FederationНациональный научно-практический центр здоровья детейРоссияNational Medical Research Center of Children's HealthRussian Federation201918022020186478484Copyright © Мурашкин Н.Н., Опрятин Л.А., Епишев Р.В., Материкин А.И., Амбарчян Э.Т., Иванов Р.А., 20202020Мурашкин Н.Н., Опрятин Л.А., Епишев Р.В., Материкин А.И., Амбарчян Э.Т., Иванов Р.А.Murashkin N.N., Opryatin L.A., Epishev R.V., Materikin A.I., Ambarchyan E.T., Ivanov R.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/2263

Пиодермии — наиболее частая причина обращения детского населения к дерматологам. Устойчивость к развитию пиодермий обусловлена кожным барьером, компонентом которого является кожная микрофлора. Состав микрофлоры кожи человека уникален и зависит от возраста, локализации на различных участках тела, условий окружающей среды. Изменение его качественного и количественного состава предрасполагает к развитию гнойничковых заболеваний кожи, отличающихся клиническим разнообразием, а при неадекватном лечении или его отсутствии — тяжелым течением и развитием осложнений. В этой связи актуальным остается выбор правильной терапии заболевания. В статье проанализированы результаты исследований, в которых изучалась эффективность различных топических антибактериальных средств. Освещены практические аспекты терапии пиодермий у детей с использованием средств для местной терапии.

Pyodermas are the most frequent reason for visiting dermatologists among children. The immunity to development of pyodermas is based on skin barrier the part of which is cutaneous microbiome. The microbiome composition is unique and depends on age, localization on various body regions, environment. The change of its qualitative and quantitative composition leads to the development of purulent dermal diseases characterized by clinical diversity and severe course and development of complications (without adequate treatment). In this regard the choice of the correct therapy remains relevant. The results of studies covering the effectiveness of various topic antibacterial agents are analysed. Practical aspects of pyodermia therapy in children using local therapy are illustrated.

детипиодермиикожный барьермикробиом кожифузидовая кислотафуцидинchildrenpyodermasskin barriercutaneous microbiomefusidic acidfucidinСтатья опубликована при поддержке компании «Лео Фарма»The article has been funded by «LEO Pharma»ReferencesBosko CA. Skin barrier insights: from bricks and mortar to molecules and microbes. J Drugs Dermatol. 2019;18(1s):s63-67.Bosko CA. Skin barrier insights: from bricks and mortar to molecules and microbes. J Drugs Dermatol. 2019;18(1s):s63-67.Norlen L. Skin barrier structure and function: the single gel phase model. J Invest Dermatol. 2001;117(4):830-836. doi: 10.1038/jid.2001.1.Norlen L. Skin barrier structure and function: the single gel phase model. J Invest Dermatol. 2001;117(4):830-836. doi: 10.1038/jid.2001.1.Elias P Feingold K, Fluhr J. In: IM Friedberg, AZ Eisen, K Wolff, et al., eds. The skin as an organ of protection. In dermatology in general medicine. New York: McGraw-Hill; 2003. Рр. 107-118.Elias P Feingold K, Fluhr J. In: IM Friedberg, AZ Eisen, K Wolff, et al., eds. The skin as an organ of protection. In dermatology in general medicine. New York: McGraw-Hill; 2003. Рр. 107-118.Boman HG. Antibacterial peptides: basic facts and emerging concepts. J Intern Med. 2003;254(3):197-215. doi: 10.1046/j.1365-2796.2003.01228.x.Boman HG. Antibacterial peptides: basic facts and emerging concepts. J Intern Med. 2003;254(3):197-215. doi: 10.1046/j.1365-2796.2003.01228.x.Harder J, Schroder JM. Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. J Leukoc Biol. 2005;77(4):476-486. doi: 10.1189/jlb.0704409.Harder J, Schroder JM. Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. J Leukoc Biol. 2005;77(4):476-486. doi: 10.1189/jlb.0704409.Gunathilake R, Schurer NY, Shoo BA, et al. pH-regulated mechanisms account for pigment-type differences in epidermal barrier function. J Invest Dermatol. 2009;129(7):1719-1729. doi: 10.1038/jid.2008.442.Gunathilake R, Schurer NY, Shoo BA, et al. pH-regulated mechanisms account for pigment-type differences in epidermal barrier function. J Invest Dermatol. 2009;129(7):1719-1729. doi: 10.1038/jid.2008.442.Korting HC, Hubner K, Greiner K, et al. Differences in the skin surface pH and bacterial microflora due to the long-term application of synthetic detergent preparations of pH 5.5 and pH 7.0. Results of a crossover trial in healthy volunteers. Acta Derm Venereol. 1990;70(5):429-431.Korting HC, Hubner K, Greiner K, et al. Differences in the skin surface pH and bacterial microflora due to the long-term application of synthetic detergent preparations of pH 5.5 and pH 7.0. Results of a crossover trial in healthy volunteers. Acta Derm Venereol. 1990;70(5):429-431.Hachem JP, Crumrine D, Fluhr J, et al. pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion. J Invest Dermatol. 2003;121(2):345-353. doi: 10.1046/j.1523-1747.2003.12365.x.Hachem JP, Crumrine D, Fluhr J, et al. pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion. J Invest Dermatol. 2003;121(2):345-353. doi: 10.1046/j.1523-1747.2003.12365.x.Gunathilake R. The human epidermal antimicrobial barrier: current knowledge, clinical relevance and therapeutic implications. Recent Pat Antiinfect Drug Discov. 2015;10(2):84-97. doi: 10.2174/1574891x10666150623093446.Gunathilake R. The human epidermal antimicrobial barrier: current knowledge, clinical relevance and therapeutic implications. Recent Pat Antiinfect Drug Discov. 2015;10(2):84-97. doi: 10.2174/1574891x10666150623093446.Basler K, Bergmann S, Heisig M, et al. The role of tight junctions in skin barrier function and dermal absorption. J Control Release. 2016;242:105-118. doi: 10.1016/j.jconrel.2016.08.007.Basler K, Bergmann S, Heisig M, et al. The role of tight junctions in skin barrier function and dermal absorption. J Control Release. 2016;242:105-118. doi: 10.1016/j.jconrel.2016.08.007.Saijo S, Tagami H Dry skin of newborn infants: functional analysis of the stratum corneum. Pediatr Dermatol. 1991;8(2): 155-159. doi: 10.1111/j.1525-1470.1991.tb00308.x.Saijo S, Tagami H Dry skin of newborn infants: functional analysis of the stratum corneum. Pediatr Dermatol. 1991;8(2): 155-159. doi: 10.1111/j.1525-1470.1991.tb00308.x.Derraik JG, Rademaker M, Cutfield WS, et al. Effects of age, gender, BMI, and anatomical site on skin thickness in children and adults with diabetes. PLoS One. 2014;9(1):e86637. doi: 10.1371/journal.pone.0086637.Derraik JG, Rademaker M, Cutfield WS, et al. Effects of age, gender, BMI, and anatomical site on skin thickness in children and adults with diabetes. PLoS One. 2014;9(1):e86637. doi: 10.1371/journal.pone.0086637.Akutsu N, Ooguri M, Onodera T, et al. Functional characteristics of the skin surface of children approaching puberty: age and seasonal influences. Acta Derm Venereol. 2009;89(1):21-27. doi: 10.2340/00015555-0548.Akutsu N, Ooguri M, Onodera T, et al. Functional characteristics of the skin surface of children approaching puberty: age and seasonal influences. Acta Derm Venereol. 2009;89(1):21-27. doi: 10.2340/00015555-0548.Grice EA, Kong HH, Conlan S, et al. Topographical and temporal diversity of the human skin microbiome. Science. 2009; 324(5931):1190-1192. doi: 10.1126/science.1171700.Grice EA, Kong HH, Conlan S, et al. Topographical and temporal diversity of the human skin microbiome. Science. 2009; 324(5931):1190-1192. doi: 10.1126/science.1171700.Marples M. The ecology of the human skin. Springfield IL; 1965. 970 р.Marples M. The ecology of the human skin. Springfield IL; 1965. 970 р.Fierer N, Hamady M, Lauber CL, Knight R. The influence of sex, handedness, and washing on the diversity of hand surface bacteria. Proc Natl Acad Sci U S A. 2008;105(46):17994-17999. doi: 10.1073/pnas.0807920105.Fierer N, Hamady M, Lauber CL, Knight R. The influence of sex, handedness, and washing on the diversity of hand surface bacteria. Proc Natl Acad Sci U S A. 2008;105(46):17994-17999. doi: 10.1073/pnas.0807920105.Agarwal S, Sharma G, Dang S, et al. Antimicrobial peptides as anti-infectives against Staphylococcus epidermidis. Med Princ Pract. 2016;25(4):301-308. doi: 10.1159/000443479.Agarwal S, Sharma G, Dang S, et al. Antimicrobial peptides as anti-infectives against Staphylococcus epidermidis. Med Princ Pract. 2016;25(4):301-308. doi: 10.1159/000443479.Bibel DJ, Miller SJ, Brown BE, et al. Antimicrobial activity of stratum corneum lipids from normal and essential fatty acid-deficient mice. J Invest Dermatol. 1989;92(4):632-638. doi: 10.1111/1523-1747.ep12712202.Bibel DJ, Miller SJ, Brown BE, et al. Antimicrobial activity of stratum corneum lipids from normal and essential fatty acid-deficient mice. J Invest Dermatol. 1989;92(4):632-638. doi: 10.1111/1523-1747.ep12712202.Bibel DJ, Aly R, Shinefield HR. Antimicrobial activity of sphin-gosines. J Invest Dermatol. 1992;98(3):269-273. doi: 10.1111/1523-1747.ep12497842.Bibel DJ, Aly R, Shinefield HR. Antimicrobial activity of sphin-gosines. J Invest Dermatol. 1992;98(3):269-273. doi: 10.1111/1523-1747.ep12497842.Bowen AC, Mahe A, Hay RJ, et al. The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma. PLoS One. 2015;10(8):e0136789. doi: 10.1371/journal.pone.0136789.Bowen AC, Mahe A, Hay RJ, et al. The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma. PLoS One. 2015;10(8):e0136789. doi: 10.1371/journal.pone.0136789.WHO reference number: WHO/FCH/CAH/05.12. Epidemiology and Management of common skin diseases in children in developing countries. Geneva: World Health Organisation; 2005. 54 р.WHO reference number: WHO/FCH/CAH/05.12. Epidemiology and Management of common skin diseases in children in developing countries. Geneva: World Health Organisation; 2005. 54 р.Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52. doi: 10.1093/cid/ciu444.Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52. doi: 10.1093/cid/ciu444.Дерматовенерология. Национальное руководство. Краткое издание / Под ред. Ю.С. Бутова, Ю.К. Скрипкина, О.Л. Иванова. — М.: ГЭОТАР-Медиа, 2013. — 896 с.Dermatovenerologiya. Natsional’noye rukovodstvo. Kratkoye izdaniye. Ed by YuS Butov, YuK Skripkin, OL Ivanov. Moscow: GEOTAR-Media; 2013. 896 p. (In Russ).Johnson T, Gomez B, McIntyre M, et al. The cutaneous microbiome and wounds: new molecular targets to promote wound healing. Int J Mol Sci. 2018;19(9). pii: E2699. doi: 10.3390/ijms19092699.Johnson T, Gomez B, McIntyre M, et al. The cutaneous microbiome and wounds: new molecular targets to promote wound healing. Int J Mol Sci. 2018;19(9). pii: E2699. doi: 10.3390/ijms19092699.Canesso MC, Vieira AT, Castro TB, et al. Skin wound healing is accelerated and scarless in the absence of commensal microbiota. J Immunol. 2014;193(10):5171-5180. doi: 10.4049/jimmunol.1400625.Canesso MC, Vieira AT, Castro TB, et al. Skin wound healing is accelerated and scarless in the absence of commensal microbiota. J Immunol. 2014;193(10):5171-5180. doi: 10.4049/jimmunol.1400625.Sukumaran V, Senanayake S. Bacterial skin and soft tissue infections. Aust Prescr. 2016;39(5):159-163. doi: 10.18773/austprescr.2016.058.Sukumaran V, Senanayake S. Bacterial skin and soft tissue infections. Aust Prescr. 2016;39(5):159-163. doi: 10.18773/austprescr.2016.058.Федеральные клинические рекомендации. Дерматовенерология 2015. Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд., перераб. и доп. — М.: Деловой экспресс, 2016. — 768 с.Federal'nyye klinicheskiye rekomendatsii. Dermatovene-rologiya 2015. Bolezni kozhi. Infektsii, peredavayemyye polovym putem. 5th ed. revised and updated. Moscow: Delovoy ekspress; 2016. 768 p. (In Russ).Страчунский Л.С., Дехнич А.В., Бельков Ю.А. Сравнительная активность антибактериальных препаратов, входящих в лекарственные формы для местного применения, в отношении Staphylococcus aureus: результаты российского многоцентрового исследования // Клиническая микробиология и антимикробная химиотерапия. — 2002. — Т. 4. — № 2. — С. 157-163.Strachunsky LS, Dekhnich AV, Belkova JuA, et al. Susceptibility of Staphylococcus aureus from hospitalised patients to topical antimicrobials in Russia. Clinical microbiology and antimicrobial chemotherapy. 2002;4(2):157-163. (In Russ).Perera G, Hay R. A guide to antibiotic resistance in bacterial skin infections. J Eur Acad Dermatol Venereol. 2005;19(5):531-545. doi: 10.1111/j.1468-3083.2005.01296.x.Perera G, Hay R. A guide to antibiotic resistance in bacterial skin infections. J Eur Acad Dermatol Venereol. 2005;19(5):531-545. doi: 10.1111/j.1468-3083.2005.01296.x.Avci O, Tanyildizi T, Kusku E. A comparison between the effectiveness of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma. J Dermatolog Treat. 2013;24(1):70-74. doi: 10.3109/09546634.2011.594870.Avci O, Tanyildizi T, Kusku E. A comparison between the effectiveness of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma. J Dermatolog Treat. 2013;24(1):70-74. doi: 10.3109/09546634.2011.594870.Wilkinson JD. Fusidic acid in dermatology. Br J Dermatol. 1998; 139 Suppl 53:37-40. doi: 10.1046/j.1365-2133.1998.1390s3037.x.Wilkinson JD. Fusidic acid in dermatology. Br J Dermatol. 1998; 139 Suppl 53:37-40. doi: 10.1046/j.1365-2133.1998.1390s3037.x.Godtfredsen W, Roholt K, Tybring L. Fucidin A new orally active antibiotic. Lancet. 1962;1(7236):928-931. doi: 10.1016/s0140-6736(62)91968-2.Godtfredsen W, Roholt K, Tybring L. Fucidin A new orally active antibiotic. Lancet. 1962;1(7236):928-931. doi: 10.1016/s0140-6736(62)91968-2.Sobye P. [Cutaneous staphylococcus aureus infection treated with fucidin ointment. (In Danish)]. Ugeskr Laeger. 1966; 128(7):204-206.Sobye P. [Cutaneous staphylococcus aureus infection treated with fucidin ointment. (In Danish)]. Ugeskr Laeger. 1966; 128(7):204-206.Schofer H, Simonsen L. Fusidic acid in dermatology: an updated review. Eur J Dermatol. 2010;20(1):6-15. doi: 10.1684/ejd.2010.0833.Schofer H, Simonsen L. Fusidic acid in dermatology: an updated review. Eur J Dermatol. 2010;20(1):6-15. doi: 10.1684/ejd.2010.0833.Stuttgen G, Bauer E. Penetration and permeation into human skin of fusidic acid in different galenical formulation. Arzneimittel-forschung. 1988;38(5):730-735.Stuttgen G, Bauer E. Penetration and permeation into human skin of fusidic acid in different galenical formulation. Arzneimittel-forschung. 1988;38(5):730-735.Koning S, van Suijlekom-Smit L, Nouwen J, et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ. 2002;324(7331): 203-206. doi: 10.1136/bmj.324.7331.203.Koning S, van Suijlekom-Smit L, Nouwen J, et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ. 2002;324(7331): 203-206. doi: 10.1136/bmj.324.7331.203.Vickers CF. Percutaneous absorption of sodium fusidate and fusidic acid. Br J Dermatol. 1969;81(12):902-908. doi: 10.1111/j.1365-2133.1969.tb15972.x.Vickers CF. Percutaneous absorption of sodium fusidate and fusidic acid. Br J Dermatol. 1969;81(12):902-908. doi: 10.1111/j.1365-2133.1969.tb15972.x.Alexander WD, Hutshinson JG. Staphylococcal septicaemia treated successfully with methicillin, fusidic acid, and penicillin G in combination. Lancet. 1963;1(7271):55-56. doi: 10.1016/s0140-6736(63)91184-x.Alexander WD, Hutshinson JG. Staphylococcal septicaemia treated successfully with methicillin, fusidic acid, and penicillin G in combination. Lancet. 1963;1(7271):55-56. doi: 10.1016/s0140-6736(63)91184-x.Pfaller MA, Castanheira M, Sader HS, Jones RN. Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. Int J Antimicrob Agents. 2010;35(3):282-287. doi: 10.1016/j.ijantimicag.2009.10.023.Pfaller MA, Castanheira M, Sader HS, Jones RN. Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. Int J Antimicrob Agents. 2010;35(3):282-287. doi: 10.1016/j.ijantimicag.2009.10.023.Lemaire S, van Bambeke F, Pierard D, et al. Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin. Clin Infect Dis. 2011;52 Suppl 7:S493-503. doi: 10.1093/cid/cir165.Lemaire S, van Bambeke F, Pierard D, et al. Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin. Clin Infect Dis. 2011;52 Suppl 7:S493-503. doi: 10.1093/cid/cir165.Kutty KP, Nath IV, Kothandaraman KR, et al. Fusidic acid-induced hyperbilirubinemia. Dig Dis Sci. 1987;32(8):933-938. doi: 10.1007/bf01296717.Kutty KP, Nath IV, Kothandaraman KR, et al. Fusidic acid-induced hyperbilirubinemia. Dig Dis Sci. 1987;32(8):933-938. doi: 10.1007/bf01296717.

The authors declare that there are no conflicts of interest present.